(Q34174334)

31 July 2017

1 reference

title

Bispecific antibodies engage T cells for antitumor immunotherapy (English)

1 reference

31 July 2017

1 reference

1 reference

3

Darell D Bigner

1 reference

31 July 2017

Bryan D Choi

1

1 reference

31 July 2017

Mingqing Cai

2

1 reference

31 July 2017

Ankit I Mehta

4

1 reference

31 July 2017

Chien-Tsun Kuan

5

1 reference

31 July 2017

John H Sampson

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

30 March 2011

1 reference

Expert Opinion on Biological Therapy

31 July 2017

published in

1 reference

31 July 2017

volume

11

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

843-853

1 reference

31 July 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Tumor-associated antigens and biomarkers in cancer and immune therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Graft-versus-leukemia effects of transplantation and donor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Prospects and limitations of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Antigen-processing machinery breakdown and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

A clinical and scientific overview of tositumomab and iodine I 131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Hybrid antibodies can target sites for attack by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

High level secretion of a humanized bispecific diabody from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Bifunctional antibodies: concept, production and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

EGFRvIII-targeted vaccination therapy of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Efficient expression of recombinant human monoclonal antibodies in Drosophila S2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

A revival of bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Hybrid hybridomas and their use in immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.572874

10.1517/14712598.2011.572874

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference